ファージ療法の市場規模、シェア、成長分析、製品別、タイプ別、適応疾患別、エンドユーザー別、地域別 - 産業予測 2025～2032年

ファージ療法の世界市場規模は、2023年に2,980万米ドルと評価され、2024年の3,499万米ドルから2032年には1億2,625万米ドルに成長し、予測期間（2025-2032年）のCAGRは17.4％で成長する見通しです。

世界のファージ療法市場は、公衆衛生上の差し迫った問題である抗生物質耐性の脅威の高まりに対応して急速に牽引力を増しています。成長促進要因としては、多剤耐性感染症の増加、代替抗菌療法への投資の増加、官民双方による研究開発努力の強化などが挙げられます。ファージ療法は、病原体に対する特異性が高く、正常なマイクロバイオームを維持し、副作用が少ないため、魅力的な治療選択肢となっています。特に北米と欧州では、政府のイニシアチブがイノベーションをさらに刺激しています。しかし、規制上の不確実性、限られた臨床エビデンス、物流上の課題が、普及の妨げとなっています。しかし、ゲノム解読と個別化医療の進歩がこれらの障壁を克服し、スーパーバグとの闘いと抗感染症治療の再構築におけるファージ療法の有望な未来を示すかもしれないです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩
• ケーススタディ
• 特許分析

ファージ療法市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 大腸菌
• 黄色ブドウ球菌
• サルモネラ
• 緑膿菌
• その他

ファージ療法市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• DsDNAバクテリオファージ
• SsDNAバクテリオファージ
• SsRNAバクテリオファージ
• その他

ファージ療法市場規模：適応疾患別& CAGR（2025-2032）

• 市場概要
• 尿路感染症
• 慢性中耳炎
• 慢性潰瘍性大腸炎
• 骨感染症
• 創傷・皮膚感染症
• 嚢胞性線維症
• その他の適応疾患

ファージ療法市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院とクリニック
• 調査・学術機関
• その他

ファージ療法市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Armata Pharmaceuticals（United States）
• BiomX Inc.（Israel）
• Intralytix（United States）
• Locus Biosciences（United States）
• Amplify Biosciences（United States）
• EnBiotix（United States）
• PhagoMed Biopharma（Austria）
• Transgene S.A.（France）
• Imugene Ltd（Australia）
• Evotec SE（Germany）
• Novolytics（United Kingdom）
• GangaGen Biotechnologies（India）
• Pherecydes Pharma（France）
• Eligo Bioscience（France）
• Micreos（Netherlands）
• ContraFect Corporation（United States）
• Phagomed Biopharma GmbH（Austria）
• PhagePro Inc.（United States）
• TechnoPhage（Portugal）
• Intralytix, Inc.（United States）

結論と提言

Global Phage Therapy Market size was valued at USD 29.8 million in 2023 and is poised to grow from USD 34.99 million in 2024 to USD 126.25 million by 2032, growing at a CAGR of 17.4% during the forecast period (2025-2032).

The global Phage Therapy Market is rapidly gaining traction in response to the escalating threat of antibiotic resistance, a pressing public health issue. Growth drivers include the rise of multidrug-resistant infections, increased investments in alternative antimicrobial therapies, and enhanced R&D efforts from both public and private sectors. Phage therapy offers high specificity against pathogens, maintains the normal microbiome, and has minimal side effects, making it an attractive treatment option. Government initiatives, particularly in North America and Europe, further stimulate innovation. However, regulatory uncertainties, limited clinical evidence, and logistical challenges hinder widespread adoption. Yet, advancements in genome sequencing and personalized medicine may overcome these barriers, signaling a promising future for phage therapy in combating superbugs and reshaping anti-infective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Phage Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Phage Therapy Market Segments Analysis

Global Phage Therapy Market is segmented by Product, Type, Disease Indication, End User and region. Based on Product, the market is segmented into Escherichia coli, Staphylococcus aureus, Salmonella, Pseudomonas aeruginosa and Others. Based on Type, the market is segmented into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage and Others. Based on Disease Indication, the market is segmented into Urinary Tract Infections, Chronic Otitis, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis and Other Disease Indications. Based on End User, the market is segmented into Hospital & Clinics, Research & Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Phage Therapy Market

The global phage therapy market is primarily driven by the rising threat of antimicrobial resistance (AMR), which occurs when bacteria evolve to resist antibiotics, complicating the treatment of infections. The misuse and overprescription of these medications have led to a significant rise in AMR cases, resulting in increased mortality rates, the spread of diseases, and escalating healthcare expenses. The World Health Organization projects that by 2050, AMR could cause up to 10 million deaths annually. As such, there is a growing need for alternative treatments like phage therapy to address these challenges and manage the increasing prevalence of chronic infections.

Restraints in the Global Phage Therapy Market

One of the primary obstacles facing the global phage therapy market is the insufficient clinical evidence supporting its efficacy and safety. Currently, most available research is limited to small-scale studies or compassionate use cases, which often lack the rigorous testing found in large randomized controlled trials. This deficiency undermines the confidence of healthcare professionals and regulatory bodies in phage treatments. Consequently, this skepticism hampers efforts to gain regulatory approval, establish acceptance among practitioners, and scale the therapy for broader use. As a result, the commercial introduction of phage therapy and its integration into standard treatment protocols are significantly hindered.

Market Trends of the Global Phage Therapy Market

The Global Phage Therapy market is witnessing a significant trend towards the integration of artificial intelligence and bioinformatics, revolutionizing treatment specificity and efficacy. As developers increasingly utilize AI-assisted phage-host prediction programs and automated screening platforms, the acceleration of phage selection and development is becoming more efficient and cost-effective. This technological innovation not only reduces development timelines but also enhances therapeutic precision, making phage therapy a promising component of personalized medicine. As a result, the market is poised for substantial growth, reflecting the rising demand for targeted treatments in the face of antibiotic resistance and complex infectious diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Studies
• Patent Analysis

Global Phage Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Escherichia coli
• Staphylococcus aureus
• Salmonella
• Pseudomonas aeruginosa
• Others

Global Phage Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• DsDNA Bacteriophage
• SsDNA Bacteriophage
• SsRNA Bacteriophage
• Others

Global Phage Therapy Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Urinary Tract Infections
• Chronic Otitis
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Other Disease Indications

Global Phage Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital & Clinics
• Research & Academic Institutes
• Others

Global Phage Therapy Market Size & CAGR (2025-2032)

• North America (Product, Type, Disease Indication, End User)
  • US
  • Canada
• Europe (Product, Type, Disease Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Disease Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Disease Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Disease Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Armata Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomX Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amplify Biosciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EnBiotix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagoMed Biopharma (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene Ltd (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novolytics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GangaGen Biotechnologies (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pherecydes Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eligo Bioscience (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Micreos (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ContraFect Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phagomed Biopharma GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PhagePro Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TechnoPhage (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intralytix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations